C
Courtney A. Cohen
Researcher at United States Army Medical Research Institute of Infectious Diseases
Publications - 16
Citations - 824
Courtney A. Cohen is an academic researcher from United States Army Medical Research Institute of Infectious Diseases. The author has contributed to research in topics: Epitope & Cerium oxide. The author has an hindex of 9, co-authored 13 publications receiving 248 citations. Previous affiliations of Courtney A. Cohen include Virginia College & Virginia Tech.
Papers
More filters
Journal ArticleDOI
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
Kathryn Westendorf,Stefanie Zentelis,Lingshu Wang,Denisa Foster,Peter Edward Vaillancourt,Matthew Wiggin,Erica Lovett,R. van der Lee,Jorg Hendle,A. Pustilnik,J. Michael Sauder,Lucas Kraft,Yu Ri Hwang,Robert W. Siegel,Jinbiao Chen,Beverly A. Heinz,Richard E. Higgs,Nicole L. Kallewaard,Kevin R. Jepson,Rodrigo Goya,Maia A. Smith,D. W. Collins,Davide Pellacani,Ping Xiang,Valentine de Puyraimond,Marketa Ricicova,Lindsay DeVorkin,Caitlin Jean Pritchard,Aoise O’Neill,Kush Dalal,Pankaj Panwar,Harveer Singh Dhupar,Fabian A. Garces,Courtney A. Cohen,John M. Dye,Kathleen E Huie,Catherine V. Badger,Darwyn Kobasa,Jonathan Audet,J. J. Freitas,Saleema Hassanali,Ina E. Hughes,Luis Munoz,Holly C. Palma,Bharathi Ramamurthy,Robert W. Cross,Thomas W. Geisbert,Vineet Menacherry,Kumari G. Lokugamage,Viktoriya Borisevich,Iliana Lanz,Lisa Anderson,Payal Sipahimalani,Kizzmekia S. Corbett,Eun Sung Yang,Yi Zhang,Wei Shi,Tongqing Zhou,Misook Choe,John Misasi,Peter D. Kwong,Nancy J. Sullivan,Barney S. Graham,Tara L. Fernandez,Carl L. Hansen,Ester Falconer,John R. Mascola,Bryan Edward Jones,Bryan C. Barnhart +68 more
TL;DR: In this paper , the authors used a high-throughput B cell screening pipeline to identify a highly potent SARS-CoV-2 spike glycoprotein receptor binding domain (RBD)-specific antibody.
Posted ContentDOI
LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants
Kathryn Westendorf,Stefanie Žentelis,Denisa Foster,Peter Edward Vaillancourt,Wiggin M,Erica Lovett,van der Lee R,Jorg Hendle,A. Pustilnik,Sauder Jm,Lucas Kraft,Yuri Hwang,Robert W. Siegel,Chen J,Beverly A. Heinz,Richard E. Higgs,Kalleward N,Kevin R. Jepson,Rodrigo Goya,Maia A. Smith,David Collins,Davide Pellacani,Ping Xiang,de Puyraimond,Marketa Ricicova,Devorkin L,Pritchard C,O’Neill A,Dalal K,Panwar P,Dhupar H,Garces Fa,Courtney A. Cohen,John M. Dye,Kathleen E. Huie,Catherine V. Badger,Darwyn Kobasa,Darwyn Kobasa,Jonathan Audet,Jonathan Audet,Freitas Jj,Saleema Hassanali,Ina Hughes,Munoz L,Palma Hc,Bharathi Ramamurthy,Cross Rw,Cross Rw,Geisbert Tw,Geisbert Tw,Menacherry,Kumari G. Lokugamage,Borisevich,Lanz I,Lisa Anderson,Sipahimalani P,Kizzmekia S. Corbett,Lingshu Wang,Eun Sung Yang,Yanzhao Zhang,Wei Shi,Barney S. Graham,Mascola,Fernandez Tl,Carl L. Hansen,Ester Falconer,Bryan Edward Jones,Bryan C. Barnhart +67 more
TL;DR: The LY-CoV1404 (also known as bebtelovimab) is a highly potent, neutralizing, SARS CoV-2 spike glycoprotein receptor binding domain (RBD)-specific antibody identified from a convalescent COVID-19 patient sample, obtained approximately 60 days after symptom onset as mentioned in this paper.
Posted ContentDOI
LY-CoV1404 potently neutralizes SARS-CoV-2 variants
Kathryn Westendorf,Stefanie Žentelis,Denisa Foster,Peter Edward Vaillancourt,Matthew Wiggin,Erica Lovett,Robin van der Lee,Jorg Hendle,A. Pustilnik,J. Michael Sauder,Lucas Kraft,Yuri Hwang,Robert W. Siegel,Jinbiao Chen,Beverly A. Heinz,Richard E. Higgs,Nicole Kalleward,Kevin R. Jepson,Rodrigo Goya,Maia A. Smith,David Collins,Davide Pellacani,Ping Xiang,Valentine de Puyraimond,Marketa Ricicova,Lindsay Devorkin,Caitlin Pritchard,Kush Dalal,Pankaj Panwar,Harveer Dhupar,Fabian A. Garces,Courtney A. Cohen,John M. Dye,Kathleen E. Huie,Catherine V. Badger,Darwyn Kobasa,Darwyn Kobasa,Jonathan Audet,Jonathan Audet,Joshua J. Freitas,Saleema Hassanali,Ina Hughes,Luis Munoz,Holly C. Palma,Bharathi Ramamurthy,Robert W. Cross,Robert W. Cross,Thomas W. Geisbert,Thomas W. Geisbert,Vineet Menacherry,Kumari Lokugamage,Viktoriya Borisevich,Iliana Lanz,Lisa Anderson,Payal Sipahimalani,Kizzmekia S. Corbett,Lingshu Wang,Eun Sung Yang,Yi Zhang,Wei Shi,Barney S. Graham,John R. Mascola,Tara L. Fernandez,Carl L. Hansen,Ester Falconer,Bryan Edward Jones,Bryan C. Barnhart +66 more
TL;DR: The LY-CoV1404 as discussed by the authors antibody is a highly potent, neutralizing, SARS CoV-2 spike glycoprotein receptor binding domain (RBD)-specific antibody identified from a convalescent COVID-19 patient approximately 60 days after symptom onset.
Journal ArticleDOI
Treatment of Neurodegenerative Disorders with Radical Nanomedicine
TL;DR: The work on the biological antioxidant actions of cerium oxide nanoparticles in extension of cell and organism longevity, protection against free radical insult, and protection against trauma‐induced neuronal damage are summarized.
Journal ArticleDOI
Intra-abdominal fat depots represent distinct immunomodulatory microenvironments: a murine model.
TL;DR: In this paper, the leukocyte and progenitor populations in the stromal vascular fraction (SVF) of peritoneal serous fluid (PSF), parametrial (pmWAT), retroperitoneal (rpWAT) and omental (omWAT)) were characterized using FACS analysis.